Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD 568.97
+3.01 (0.53%)
At close: Sep 5, 2025
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
683.37K GBP
Profits / Employee
214.35K GBP
Market Cap
43.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Regeneron Pharmaceuticals News
- 4 days ago - Regeneron Announces Updated Presentation Time for Upcoming Investor Conference - GlobeNewsWire
- 4 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 5 days ago - Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback - Seeking Alpha
- 10 days ago - Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial - CNBC
- 13 days ago - Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data - Benzinga
- 13 days ago - Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam - Seeking Alpha
- 13 days ago - Regeneron's rare immune disorder therapy meets main goal of late-stage trial - Reuters